Ligand Pharmaceuticals Incorporated (LGND)

NASDAQ: LGND · IEX Real-Time Price · USD
73.10
+1.83 (2.57%)
Mar 28, 2024, 4:00 PM EDT - Market closed

Company Description

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide.

Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children.

The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19.

In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications.

The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International.

Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in Jupiter, Florida.

Ligand Pharmaceuticals Incorporated
Ligand Pharmaceuticals logo
Country United States
Founded 1987
IPO Date Nov 18, 1992
Industry Biotechnology
Sector Healthcare
Employees 58
CEO Todd C. Davis Ph.D.

Contact Details

Address:
3911 Sorrento Valley Blvd, Suite 110
San Diego, California 92121
United States
Phone 858-550-7500
Website ligand.com

Stock Details

Ticker Symbol LGND
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0000886163
CUSIP Number 53220K504
ISIN Number US53220K5048
Employer ID 77-0160744
SIC Code 2834

Key Executives

Name Position
Todd C. Davis Ph.D. Chief Executive Officer and Director
Matthew E. Korenberg President and Chief Operating Officer
Octavio Espinoza Chief Financial Officer
Andrew T. Reardon J.D. Chief Legal Officer and Secretary
Paul J. Hadden Senior Vice President of Investments and Business Development
Simon Latimer Head of Investor Relations
Todd Pettingill Director of Corporate Development
Audrey Warfield-Graham Chief People Officer
Dr. Keith Marschke Senior Vice President of Biology and Scientific Affairs
Dr. Vincent D. Antle Senior Vice President of Technical Operations and QA - Capitsol

Latest SEC Filings

Date Type Title
Mar 5, 2024 144 Filing
Mar 1, 2024 S-8 Securities to be offered to employees in employee benefit plans
Feb 29, 2024 144/A Filing
Feb 29, 2024 10-K Annual Report
Feb 28, 2024 144 Filing
Feb 28, 2024 144 Filing
Feb 27, 2024 8-K Current Report
Feb 14, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Feb 13, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 13, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals